Riminophenazine compounds: Pharmacology and anti-neoplastic potential

Critical Reviews in Oncology/Hematology

Volumn 25, Issue 1, 1997, Pages 55-67

  Van Rensburg, C E J ^a   Anderson, R ^a   O'Sullivan, J F ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

3 ANILINO 2 CYCLOHEXYLIMINO 2,10 DIHYDRO 10 PHENYLPHENAZINE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; B 4090; B 4100; B 4166; B 729; CLOFAZIMINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; LEPROSTATIC AGENT; METHOTREXATE; MITOMYCIN; PHENAZINE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; HUMAN; HUMAN CELL; INFECTION; INFLAMMATION; LEPROSY; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; NONHUMAN; REVIEW;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CLOFAZIMINE; HUMANS;

EID: 0030887404     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(96)00229-6     Document Type: Review

References (102)

1. [1] Gottesman MM. How cancer cells evade chemotherapy: Sixteenth Richard and Hilda Rosenthal Foundation Award Lecture. Cancer Res 53:747-754, 1993.
2. 2-mediated oxidative and non-oxidative mechanisms. Cancer Res 53:318-323. 1993.
3. +-adenosine triphosphatase activity in cancer cell lines in vitro. Int J Oncol 4:1115-1119, 1994.
4. [4] Barry VC, Belton JG, Conalty ML, Denneny JM, Edward DW, O'Sullivan JF, Twomey D, Winder F. A new series of phenazines (rimino-compounds) with high anti-tuberculosis activity. Nature (London) 179:1013-1015, 1957.
5. [5] Van Rensburg CEJ, Joone GK, O'Sullivan JF, Anderson R. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob Agents Chemother 36:2729-2735, 1992.
6. [6] Zeis BM, Anderson R, O'Sullivan JF. Prooxidative activities of 10 phenazine derivatives relative to that of clofazimine. Antimicrob Agents Chemother 31:789-793, 1987.
7. [7] Savage JE, O'Sullivan JF, Zeis BM, Anderson R. Investigation of the structural properties of dihydrophenazines which contribute to their pro-oxidative interactions with human phagocytes. J Antimicrob Chemother 26:691-700, 1989.
8. [8] Nolan TJ, Algar J, McCann P, Manahan WA, Nolan N. The chemical constituents of lichens found in Ireland: Beullia canescens Part 3. Sci Proc R Dublin Soc 24:319-334, 1948.
9. [9] Fischer O, Dischinger A. Ueber die Oxydationsproducte des Orthoamidodiphenylamins. Ber Dtsch Chem Ges 29:1602-1613, 1896.
10. [10] Barry VC, Belton JG, Conalty ML, Twomey D. Antitubercular activity of oxidation products of o-phenylenediamines. Nature (London) 162:622-624, 1948.
11. [11] Barry VC, Belton JG. Antitubercular substances X. Proc R Irish Acad 556:149-156, 1953.
12. [12] Barry VC, Belton JG, Chambers JF, Kelly R, Twomey D. Antitubercular substances XI. Proc R Irish Acad 55B:157-164. 1953.
13. [13] Allday EJ, Barnes J. Treatment of leprosy with B283. Irish J Med Sci 421-425, 1952.
14. [14] Barry VC, Belton JG, O'Sullivan JF, Twomey D. The oxidation of derivatives of o-phenylenediamine Part III. J Chem Soc 896-899, 1956.
15. [15] Barry VC, Belton JG, O'Sullivan JF, Twomey D. The oxidation of derivatives of o-phenylenediamine Part IV. J Chem Soc 3347-3350, 1956.
16. 2-substituted anilinoaposafranines. J Chem Res (S):52-53, 1984.
17. [17] Barry VC, Belton JG, O'Sullivan JF. Twomey D. The oxidation of derivatives of o-phenylenediamine Part V. J Chem Soc 859-863, 1958.
18. [18] O'Sullivan JF, Morrison NE, Conalty ML. Clofazimine analogues active against a clofazimine-resistant organism. J Med Chem 31:567-572, 1988.
19. [19] Barry VC, Belton JG, Conalty ML, et al. A new series of phenazines with high antituberculosis activity. Nature (London) 179:1013-1015, 1957.
20. [20] Barry VC, Conalty ML. Antituberculosis activity in the phenazine series. Am Rev Tuberc 78:62-73, 1958.
21. [21] Gangadharam PRJ, Ashtekar D, O'Sullivan JF. In vitro, in vivo and intracellular chemotherapeutic activity of B746, a clofazimine analogue against Mycobacterium avium complex. Tuberc Lung Dis 73:192-199, 1992.
22. [22] Lindholm-Levy PJ, Heifets LB. Clofazimine and other rimino-compounds: Minimal inhibitory and minimal bactericidal concentrations at different pHs for Mycobacterium avium complex. Tubercle 69:179-186, 1988.
23. [23] O'Sullivan JF, Conalty ML, Morrison NE. Clofazimine analogues active against a clofazimine-resistant organism. J Med Chem 31:567-572, 1988.
24. [24] Byrne J, Conalty ML, O'Sullivan JF. Absorption studies with clofazimine analogues: Selection of compounds for in vivo testing against M. leprae. Proc R Irish Acad 896:115-118, 1989.
25. [25] Franzblau SG, White KE, O'Sullivan JF. Structure-activity relationships of tetramethylpiperidine-substituted phenazines against M. leprae in vitro. Antimicrob Agents Chemother 33:2004-2005, 1989.
26. [26] O'Connor R, O'Sullivan JF, O'Kennedy R. The pharmacology, metabolism and chemistry of clofazimine. Drug Metab Rev 27:591-614, 1995.
27. [27] Yawalkar SJ, Vischer W. Lamprene (clofazimine) in leprosy. Lepr Rev 50:135-144, 1978.
28. [28] Schaad-Lanyi Z, Dieterle W, Dubois JP, Theobald W. Vischer W. Pharmacokinetics of clofazimine in healthy volunteers. Int J Lepr 55:9-15, 1987.
29. [29] Barry VC, Conalty ML. The antimycobacterial activity of B663. Lepr Rev 36:3-7, 1965.
30. [30] Mansfield RE. Tissue concentrations of clofazimine (B663) in man. Am J Trop Med Hyg 23:1116-1119, 1974.
31. [31] Garrelts JC. Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. DICP Ann Pharmacother 25:525 531, 1991.
32. [32] Holdiness MR. Adverse cutaneous reactions to antituberculosis drugs: a review. Int J Dermatol 24:280-285. 1985.
33. [33] Holdiness MR. Clinical pharmacokinetics of clofazimine. A review. Clin Pharmacokinet 16:74-85, 1989.
34. [34] Hastings RC, Jacobson RK, Trautman JR. Long term clinical toxicity studies with clofazimine in leprosy. Int J Lepr 44:287-293, 1976.
35. [35] Moore VJ. A review of side-effects experienced by patients taking clofazimine. Lepr Rev 54:327-335. 1983.
36. [36] Peters JH, Gordon GR, Murray JF. Simmons VF. Mutagenic activity of antileprosy drugs and their derivatives. Int J Lepr 51:45-53, 1983.
37. [37] Browne SG, Hogerzeil LM. B663 in the treatment of leprosy: preliminary report of a pilot trial. Lepr Rev 33:6-16, 1962.
38. [38] Jacobson RR, Hastings RC. Rifampicin resistant leprosy. Lancet 2:1304-1305, 1976.
39. [39] Pearson JMH, Haile GS, Rees RJW. Primary dapsone resistant leprosy. Lepr Rev 48:129-132, 1977.
40. [40] Pattyn RS, Colston MJ. Cross-resistance amongst thiambutosine, thiacetazone, ethionamide and prothionamide with Mycobacterium leprae. (Letter) Lepr Rev 49:324-326, 1978.
41. [41] Warndorff-Van Diepen T. Clofazimine resistant leprosy - a case report. Int J Lepr 50:123-127, 1982.
42. [42] World Health Organization. Wkle Epid Rep 62:101-108, 1987.
43. [43] Katoch K, Nataranjan M, Bagga A, Katoch VM. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT. Int J Lepr Mycobact Dis 59:248-254, 1991.
44. [44] Cartel JL, Spiegel A, Nguyen Ngoe L, Moulia-Pelat JP, Martin PM. Grosset JH. Leprosy in French Polynesia. The possible impact of multidrug therapy on epidemiological trends. Lepr Rev 63:223-230, 1992.
45. [45] Venkateswarlu B, Venkataramana D, Rao AV, Prabhakar MC, Reddy BM. Role of rifampicin and clofazimine ointment in the treatment of leprosy. Int J Lepr Other Mycobact Dis 60:269-270, 1992.
46. [46] Freerksen E, Seydel JK. Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine. Arzneim-Forsch/Drug Res 42(II):1243-1245, 1992.
47. [47] Young LS. Mycobacterium avium complex infection. J Infect Dis 157:863-867, 1988.
48. [48] Horsburgh CR Jr, Havlik JA, Ellis DA, Kennedy E, Fann SA, Dubois RE, Thompson SE. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Resp Dis 144:557-559, 1991.
49. [49] Woods GL, Washington JA. Mycobacteria other than Mycobacterium tuberculosis: review of the microbiological and clinical aspects. Rev Infect Dis 9:275-294, 1987.
50. [50] Dautzenberg B. Truffot C. Mignon A, Rozenbaum W, Katlama C, Perronne C. Parrot R, Grosset J. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Tubercle 72:168-175, 1991.
51. [51] Yarrish RL, Shay W, LaBombardi VJ, Meyerson M, Miller DK. Larone D. Osteomyelitis caused by Mycobacterium haemophilum: successful therapy in two patients with AIDS. AIDS (US) 6:557-561, 1992.
52. [52] DeBergeyck E, Janssens PG. De Muynck A. Radiological abnormalities of the ileum associated with the use of clofazimine in the treatment of skin ulceration due to Mycobacterium ulcerans. Lepr Rev 51:221-228, 1980.
53. [53] Revill WDL, Morrow RH, Pike MC, Ateng J. A controlled trial treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 2:873-877, 1973.
54. [54] Van Rensburg CEJ. Van Straten A. An in vitro investigation of the susceptibility of Enterococcus faecalis to clofazimine and B669. J Antimicrob Chemother 33:356-358. 1994.
55. [55] De Bruyn EE, Steel HC, Van Rensburg CEJ, Anderson R. Clofazimine and B669 inhibit potassium transport in Grampositive bacteria by a lysophospholipid-dependent mechanism. J Antimicrob Chemother 38:349 362, 1996.
56. [56] Imkamp FMJH. A treatment of corticosteroid dependent lepromatous patients in persistent erythema nodosum leprosum. Lepr Rev 39:119-125, 1968.
57. [57] Mackey JP, Barnes J. Clofazimine in the treatment of discoid lupus erythematosus. Br J Dermatol 91:93-96, 1974.
58. [58] Krivanek J, Paver WKA, Dossard S, Cairns G. Clofazimine (Lamprene) in the treatment of discoid lupus erythematosus. Aust J Dermatol 17:108-110, 1976.
59. [59] Michaëlsson G, Molin L, Ohman S, Gip L, Lindström B, Skogh M, Trolin I. Clofazimine: a new agent for the treatment of pyoderma gangrenosum. Arch Dermatol 112:344-349, 1976.
60. [60] Mensing H. Clofazímine in dermatitis ulcerosa (pyoderma gangrenosum). Open clinical trial. Dermatologica 177:232-236, 1988.
61. [61] Kaplan B, Trau H, Sofer E, Feinstein A, Schewach-Millet M. Treatment of pyoderma gangrenosum with clofazimine. Int J Dermatol 31:591-593, 1992.
62. [62] Landow RK. New drugs for dermatologic diseases. Dermatol Clin 6:575-584, 1988.
63. [63] Tausch I, Sonnichsen N. Experiences with clofazimine therapy of Melkersson-Rosenthal syndrome (German). Hautarzt 43:194-198, 1992.
64. [64] Mensing H. Clofazimine-therapeutic alternative in necrobiosis lipoidica and granuloma anulare. Hautarzt 40:99-103, 1989 (in German).
65. + adenosine triphosphatase activity of human lymphocytes by a lysophospholipid-dependent mechanism. Biochem Pharmacol 46:2029-2038, 1993.
66. 2 activity and superoxide generation. J Infect Dis 167:899-904, 1993.
67. 2+-dependent protein kinase. Science 224:622-625, 1984.
68. [68] Oishi K, Raynor RL, Charp PA. Kuo JF. Regulation of protein kinase C by lysophospholipids. Potential role in signal transduction. J Biol Chem 263:6865-6871, 1988.
69. [69] Weiss SJ, Slivka A. Monocyte and granulocyte-mediated tumor cell destruction. J Clin Invest 69:255-262, 1982.
70. [70] Van Rensburg CEJ, Theron AJ. Chasen M. The riminophenazine agents clofazimine and B669 inhibit the proliferation of intrinsically multidrug resistant carcinoma cell lines. Oncol Rep 3:103-106, 1996.
71. [71] Sri-Pathmanathan RM. Plump JA, Fearon KCH. Clofazimine alters the energy metabolism and inhibits the growth rate of a human lung-cancer cell line in vitro and in vivo. Int J Cancer 56:900-905, 1994.
72. [72] Sweadner KJ. Goldin SM. Active transport of sodium and potassium ions. New Eng J Med 301:777-783, 1980.
73. [73] Cartman ML, Morris JA, Oates K, Huddart H, Staff WG. Electrolyte levels in neoplastic and non-neoplastic human urothelium after ouabain treatment: X-ray microanalysis of bulk hydrated samples. Ultrastruct Pathol 18:461-466, 1994.
74. [74] Sandström P-E, Johnsson Ö. Grankvist K, Henriksson R. Identification of potassium flux pathways and their role in the cytotoxicity of estramustine in human malignant glioma, prostatic carcinoma and pulmonary carcinoma cell lines. Eur J Cancer 30A: 1822-1826, 1994.
75. [75] Kimelberg HK. Protein liposome interactions and their relevance to the structure and function of cell membranes. Mol Cell Biochem 10:171-190, 1976.
76. [76] Oishi K. Zheng B, Kuo JF. Inhibition of Na, K-ATPase and sodium pump by protein kinase C regulators sphingosine. lysophosphatidylcholine and oleic acid. J Biol Chem 265:70-75. 1990.
77. +-pump activity by lysophosphatidylcholines. Methods Find Exp Clin Pharmacol 12:281-186, 1990.
78. [78] Van Rensburg CEJ, Durandt C, Garlinski PJ, O'Sullivan JF. Evaluation of the antineoplastic activities of the riminophenazine agents clofazimine and B669 in tumor-bearing rats and mice. Int J Oncol 3:1011-1013, 1993.
79. [79] Zheng B, Oishi K, Shoji M. Ehbl H. Berdel WE, Hajdu J, Vogler WR, Kuo JF. Inhibition of protein kinase C, (sodium plus potassium )-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues. Cancer Res 50:3025-3031, 1991.
80. [80] Diomede L, Bianchi R, Modest EJ, Piovani B, Bubbo F, Salmona M. Modulation of ATPase activity by cholesterol and synthetic ether lipids in leukemic cells. Biochem Pharmacol 43:803-807, 1992.
81. [81] Berdel WE, Bausert WR, Weltzien HU, Modolell ML, Widmann KH, Munder PG. The influence of alkyllysophospholipid and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma. Eur J Cancer 16:1199-1204, 1980.
82. [82] Unger C, Damenz W, Fleer EAM et al. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the anti-neoplastic activity in vitro and in vivo. Acta Oncol 28:213-217, 1989.
83. [83] Dummer R, Röger J, Vogt T et al. Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas. In: Eibl H, Hilgard P, Unger C. eds. Alkylphosphocholines. New Drugs in Cancer Therapy. Vol. 34, Prog Exp Tumor Res Basel, Karger, 1992; 160-169.
84. +-adenosine triphosphatase is a possible mechanism of immunosuppressive activity of cyclosporin A. Mol Pharmacol 44:605-614, 1993.
85. +-adenosine triphosphatase activity in cultured hamster renal tubular cells. Toxicol Appl Pharmacol 125:176-183, 1994.
86. [86] Twentyman PR, Wright KA, Wallace HM. Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, on the growth of parent and multidrug resistant human lung cancer cells in vitro. Br J Cancer 65:335-340, 1992.
87. [87] Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem Pharmacol 43:109-117, 1992.
88. [88] List AF, Spier C, Greer J et al. Phase I/II trial of cyclosporin as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652-1660, 1993.
89. [89] Pearson CK, Cunningham C. Multidrug resistance during cancer chemotherapy - biotechnological solutions to a clinical problem. TIBTECH 11:511-516, 1993.
90. [90] Müller M, Meijer C, Zaman GJR, Borst P, Scheper RJ, Mulder NH, De Vries EGE, Jansen PLM. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91:13033-13037, 1994.
91. [91] Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, Van Heijningen THM, Van Kalken CK, Slovak ML, De Vries EGE, Van der Valk P, Meijer CJLM, Pinedo HM. Overexpression of a Mr 110000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1455-1479, 1993.
92. [92] Kramer RA, Zakher J, Kim G. Role of glutathione-redox cycle in acquired and de novo multidrug resistance. Science 241:694-697, 1988.
93. [93] Morrow CS, Cowan KH. Glutathione S-transferases and drug resistance. Cancer Cells 2:15-22, 1990.
94. [94] Pessina A. Topoisomerase I in multiple drug resistance. Cytotechnology 12:127-135, 1993.
95. [95] Hofman GA, Mettern MR. Topoisomerase II in multiple drug resistance. Cytotechnology 12:137-154, 1993.
96. [96] Van Rensburg CEJ, Anderson R, Myer MS, Jooné GK, O'Sullivan JF, The riminophenazine agents clofazimine and B669 reverse acquired multidrug resistance in a human lung cancer cell line. Cancer Lett 85:59-63, 1994.
97. [97] Myer MS, Van Rensburg CEJ. Chemosensitizing interactions of clofazimine and B669 with human K562 erythroleukaemia cells with varying levels of expression of P-glycoprotein. Cancer Lett 99:73-78, 1996.
98. [98] Sikic BI. Modulation of multdrug resistance: at the threshold. J Clin Oncol 11:1629-1635, 1993.
99. [99] Durandt C, Van Rensburg CEJ, O'Sullivan JF, Anderson R. Novel riminophenazine compounds with improved anti-tumour properties. SA J Sci 92:257-259, 1996.
100. [100] O'Sullivan JF, Franzblau SG, White KE. New clofazimine analogues: a structure activity study in vitro. Health Cooperation Papers 12:191-197, 1992.
101. [101] O'Connor R, O'Sullivan JF. O'Kennedy R. Determination of serum and tissue levels of phenazines including clofazimine. Chromatography (in press).
102. [102] O'Connor R, O'Sullivan JF, O'Kennedy R. A preliminary investigation of selected anti-mycobacterial phenazines. Int J Lepr (in press). Constance Elizabeth Jansen van Rensburg is a Professor in the Department of Immunology of the University of Pretoria. Her responsibilities in this department include teaching undergraduate and postgraduate students in immunology, supervision of research programs, and diagnosis of leukemias and cell-mediated immune deficiencies by flow-cytometric analysis. She is the author or co-author of over 45 scientific papers. She is a member of the American Association of Cancer Research and the International Society of Flow Cytometry as well as various national societies. Her primary research interests are immunopharmacology and experimental oncology.